Observations from the OMERACT Drug Safety Summit, May 2008

Lee S. Simon, C. Vibeke Strand, Maarten Boers, Peter M. Brooks, David Henry, Peter S. Tugwell

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)2110-2113
Number of pages4
JournalJournal of Rheumatology
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2009
Externally publishedYes

Fingerprint Dive into the research topics of 'Observations from the OMERACT Drug Safety Summit, May 2008'. Together they form a unique fingerprint.

  • Cite this

    Simon, L. S., Strand, C. V., Boers, M., Brooks, P. M., Henry, D., & Tugwell, P. S. (2009). Observations from the OMERACT Drug Safety Summit, May 2008. Journal of Rheumatology, 36(9), 2110-2113. https://doi.org/10.3899/jrheum.090590